Public advisory -Teva Octreotide for injectable suspension recalled due to potential drug quality issues

PR Newswire
Today at 6:30pm UTC

Public advisory -Teva Octreotide for injectable suspension recalled due to potential drug quality issues

Canada NewsWire

OTTAWA, ON, Jan. 13, 2026 /CNW/ - 

Summary

  • Product: All strengths of Teva Octreotide for Injectable Suspension Kit (DIN 02503751, 02503778 and 0253786) with the lot numbers noted below.
  • Issue: Health products – Product quality
  • What to do: If you have an affected product, do not use it. Speak to your health care professional immediately to obtain an alternative or replacement product. Seek medical attention if you have used this product and are experiencing symptoms of infection, or other unexpected symptoms or side effects.

All strengths of Teva Octreotide for Injectable Suspension Kit (DIN 02503751, 02503778 and 0253786) (CNW Group/Health Canada (HC))

Affected products

Product

DIN

UPC

Lot

Expiration date

Teva Octreotide for injection 10 mg/vial - kit

02503751

068510998460

4401203R

4401202

4400915

31 Oct 2026

30 Sep 2026

31 Aug 2026

Teva Octreotide for injection 20 mg/vial - kit

02503778

068510998477

4501460

4401309

4401501

4401231

4401065

31 Mar 2027

30 Sep 2026

31 Oct 2026

30 Sep 2026

30 Sep 2026

Teva Octreotide for injection 30 mg/vial - kit

02503786

068510998484

4501296

4401394

4500804

4500219

4401208

4500218

4401207

4400955

4400918

28 Feb 2027

31 Oct 2026

31 Oct 2026

30 Sep 2026

30 Sep 2026

30 Sep 2026

30 Sep 2026

30 Sep 2026

31 Aug 2026

Issue

Teva Canada Limited is recalling all strengths (lots listed above) of the prescription drug Octreotide as a precautionary measure due to deficiencies in Good Manufacturing Practices (GMP) identified at its foreign manufacturing site. GMPs ensure drugs meet the appropriate quality standards for their intended use before they are sold. The deficiencies identified could lead to potential quality issues with the products, including microbiological contamination (leading to compromised sterility), contamination with foreign particles and concerns related to dosing accuracy.

Potential serious health risks associated with these deficiencies include:

  • Skin and muscle infections at the injection site, including cellulitis or abscess
  • Severe blood infection
  • Blood clots
  • Hypersensitivity reactions, including life threatening allergic reactions
  • Inflammatory reactions/lumps at the injection site
  • Lack of therapeutic effect due to an insufficient dose
  • Symptoms of overdose, such as hot flushes, frequent urination, fatigue, depression, anxiety and lack of concentration, or worsened side effects.

Teva Octreotide acetate for injectable suspension is a long-acting prescription medication used to treat certain hormone-related disorders, including acromegaly (a condition caused by too much growth hormone), as well as severe diarrhea and flushing caused by certain tumors.

Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventive actions. The Department will inform the public if any new health risks are identified.

 What you should do

  • If you have an affected product, do not use it. Speak to your health care professional immediately to obtain an alternative or replacement product. If you are unsure whether your product is affected, check with your pharmacy.
  • Seek medical attention if you have used this product and are experiencing symptoms of infection, or other unexpected symptoms or side effects.
  • Return affected product(s) to the pharmacy where it was purchased for proper disposal.
  • Consult a health care professional if you have used the affected product and have health concerns.
  • Contact Teva Canada Limited by calling toll-free at 1-800-268-4127, option 3, or by email at druginfo@tevacanada.com, if you have questions about this recall.
  • Report any health product-related side effects or complaints to Health Canada.

SOURCE Health Canada (HC)